Published on Microbicide Trials Network (http://www.mtnstopshiv.org)

HPTN 059

The trial, now complete, assessed the safety and acceptability of the antiretroviral-based candidate microbicide tenofovir topical gel used either daily or before each act of sex in 200 HIV-negative women at three sites in India and the United States.

See

Trial finds tenofovir gel safe for daily use and most women adhered to study regimens [1]

HPTN 059 Backgrounder [2]

HPTN 059 Q&A [3]

See Also

HPTN 059 Protocol [4]

Printer-friendly version [5]

Source URL: http://www.mtnstopshiv.org/news/studies/hptn059

Links:
[1] http://www.mtnstopshiv.org/node/359
[2] http://www.mtnstopshiv.org/news/studies/hptn059/backgrounder
[3] http://www.mtnstopshiv.org/news/studies/hptn059/qa
[4] http://www.mtnstopshiv.org/sites/default/files/attachments/HPTN059v2_0.pdf
[5] http://www.mtnstopshiv.org/print/812

Media Contacts:

Lisa Rossi -- Office: +1 412 641-8940 -- Mobile: +1 412 916-3315 -- Email: rossil@upmc.edu

Clare Collins -- Office: +1 412 641-7299 -- Mobile: +1 412 770-8643 -- Email: collcx@upmc.edu